CCR5 Ligand Levels and Immune Response to HIV Vaccines [Revised Proposal]

Michael Pensiero
301-435-3749
[email protected]

SUMMARY STATEMENT
(Privileged Communication )

Release Date: 08/23/2002

I / 1ZI

Application Number: 1 R01 A1052038-01A1

GARZINO-DEMO,-ALFREDO PHD
UNIV OF MD BIOTECH INST
INST OF HUMAN VIROLOGY
725 W LOMBARD ST
BALTIMORE, MD 21201

Review Group: ZRG1 VACC (01)
Center for Scientific Review Special Emphasis Panel
AIDS - EXP. REV.
Meeting Date: 07/17/2002 RFAIPA: PA01-055
Council: OCT 2002 PCC: AI4E
Requested Start: 01/01/2003
Project Title: CCR5 Ligand Levels and Immune Response to HIV Vaccines
SRG Action: Priority Score: 274 Percentile: 73.4
Human Subjects: 30-Human subjects involved - Certified, no SRG concerns
Animal Subjects: 10-No live vertebrate animals involved for competing appl.
Gender: 1A-Both genders, scientifically acceptable
Minority: 1A-Minorities and non-minorities, scientifically acceptable
Children: 1A-Both Children and Adults, scientifically acceptable
Clinical Research - not NIH-defined Phase III Trial
Project Direct Costs Estimated
Year Requested Total Cost
1 200,000 297,000
2 200,000 297,000
3 200,000 297,000
4 200,000 297,000
5 200,000 297,000
TOTAL 1,000,000 1,485,000
ADMINISTRATIVE BUDGET NOTE: The budget shown is the requested budget and has not been
adjusted to reflect any recommendations made by reviewers. If an award is planned, the costs will be
calculated by Institute grants management staff based on the recommendations outlined below in the
COMMITTEE BUDGET RECOMMENDATIONS section.

NEW INVESTIGATOR